StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research note released on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Up 2.2 %
Shares of Akari Therapeutics stock opened at $2.32 on Friday. The firm’s 50 day moving average is $3.12 and its 200 day moving average is $2.73. Akari Therapeutics has a 1 year low of $1.08 and a 1 year high of $4.40.
Akari Therapeutics Company Profile
Featured Stories
- Five stocks we like better than Akari Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.